CD8A and neoplasm: Three multi-antigen DNA vaccines were designed that induced neoantigen-specific CD8+ T cell responses only (noHELP) or together with CD4+ T cell responses to either tumor-unrelated “universal” antigens (uniHELP) or MC-38-derived neoantigens (neoHELP).